 Mainz Biomed NV NASDAQ: MYNZ has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert, a detection test for colorectal cancer CRC. Mainz is currently marketing ColoAlert in Europe by partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. 